Myeloproliferative neoplasms: The era of JAK2 mutations and more…

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Myeloproliferative neoplasms: The era of JAK2 mutations and more… ; volume:29 ; number:04 ; year:2008 ; pages:4-5
Indian journal of medical & paediatric oncology ; 29, Heft 04 (2008), 4-5

Beteiligte Personen und Organisationen
Saxena, Renu
Gupta, Sanjeev Kumar

DOI
10.4103/0971-5851.51396
URN
urn:nbn:de:101:1-2022031216483175791016
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:29 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Saxena, Renu
  • Gupta, Sanjeev Kumar

Ähnliche Objekte (12)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

MPL W515 L/K mutations in myeloproliferative neoplasms

MPL W515 L/K mutations in myeloproliferative neoplasms

CALR mutations in myeloproliferative neoplasms : An unfolding story

CALR mutations in myeloproliferative neoplasms : An unfolding story

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Esophageal lesions in myeloproliferative neoplasms

Esophageal lesions in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Verbundene Objekte